
## **Thriving Sectors: Life Sciences**

Life science and cloud software companies have consistently attracted the majority of venture capital investments in the last ten years and continued to do so in 2018. Over 30% of capital raised since 2016 has gone to life science companies, with over 20 companies raising more than \$555 million. The majority of this capital was devoted to a few later-staged companies, although many earlier staged companies received funding as well, with 22 deals rounds of funding raised in amounts less than \$25 million. Within Life Sciences, the Tri-Valley fosters exceptional companies in the device space, benefiting from accommodative real estate and a diverse talent pool required as they grow. 98% of life science deals in 2018 were in the medical device space.



## Notable Life Science Investments

Year	Tri-Valley Company	Deal Size	Stage	Brief	City
2018	10x Genomics	\$50M+Debt	Series D	Genomics platform	Pleasanton
2018	BioClin (Rainier Therapeutics)	\$50M	Series B	Drug discover	San Ramon
2018	Providence Medical Tech	\$25M	Late Stage	Cervical spine surgical device	Pleasanton
2018	Unchained Labs	\$17M	Series D	Laboratory instruments	Pleasanton
2018	SafeTraces	\$10M	Series A	Edible barcode technology	Pleasanton
2017	Ankon Medical Tech	\$100M	Late Stage	Gastric diagnostic device	Pleasanton
2017	Purigen Biosystems	\$21M	Series A	DNA sample prep	Pleasanton
2017	POC Medical Systems	\$21M	Series A	Point-of-care cancer diagnostics	Livermore
2016	HealthTell	\$26M	Series B	Immune profiling	San Ramon
2016	Spirosure	\$18M	Series C	Breath-analysis disease diagnostics	Pleasanton